HGG |
CLX |
Glioma cell-lines T98 and U87 xenograft |
Jandial et al., 2018
|
HGG |
CLX |
Glioma cell-lines TG1 xenograft |
Fareh et al., 2012
|
HGG |
CLX/syngeneic |
Syngeneic glioma cell lines GL261 xenograft |
Ausman et al., 1970
|
HGG |
PDX/PDOX |
Xenograft of patient-derived GBM cells/neurospheres |
Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020
|
Pediatric tumors |
PDOX |
Xenograft of patient-derived tumor cells (from different type of pediatric glioma) |
Brabetz et al., 2018; Smith et al., 2020
|
HGG |
GEMM |
Pdgfb OE, Trp53–/–
|
Hede et al., 2009
|
HGG |
GEMM |
Pdgfb OE, Ink4a/Arf–/–, Trp53–/–, Pten–/–
|
Hambardzumyan et al., 2009
|
HGG |
GEMM |
K-Ras OE, Ink4a/Arf–/–
|
Uhrbom et al., 2005
|
HGG |
GEMM |
EGFRvIII OE, Ink4a/Arf–/–, Pten–/–
|
Zhu et al., 2009
|
HGG |
GEMM |
EGFRvIII OE, V12-Ras, Pten–/–
|
Wei et al., 2006
|
HGG |
GEMM |
Nf1+/−, Trp53+/−, Pten+/−
|
Kwon et al., 2008
|
HGG |
GEMM |
H-Ras-V12 OE, Akt OE, Trp53+/−
|
Marumoto et al., 2009
|
LGG |
GEMM |
NrasG12V OE, Idh1R132H
OE, shAtrx, shTrp53
|
Núñez et al., 2019
|
HGG |
GEBO |
EGFRvIII OE, EGFR OE, CDKN2A–/–/CDKN2B–/– or NF1–/–, TP53–/–, PTEN–/–
|
Bian et al., 2018
|
HGG |
GEBO |
H-RasG12V OE, TP53–/–
|
Ogawa et al., 2018
|
GBM |
PDO |
Patient-derived organoid |
Jacob et al., 2020
|
|
Drosophila
|
|
|
GBM |
Transgenic |
dEGFRλ, dp110CAAX, dPTEN, dRas85DN17, dRas85DV12, dRafGOF OE, dPTEN dsRNA |
Read et al., 2009, 2013
|
GBM |
Transgenic |
dRafGOF, hFGFR3-hTACC3, dEGFRACT, dPI3KACT
|
Chen et al., 2018
|
|
Zebrafish
|
|
|
GBM |
Transgenic |
HRASG12V, KRASG12V
EGFRvIII, BRAFV600E OE |
Mayrhofer et al., 2017
|
Glioma |
Transgenic |
KRASG12V OE |
Ju et al., 2015
|
Glioma |
Transgenic |
DAAkt1, DARac1 OE |
Jung et al., 2013
|
HGG/MPNSTs |
Knockout |
nf1a+/−; nf1b–/–; tp53e7/e7
|
Shin et al., 2012
|
GBM |
CLX |
Glioblastoma cell line U373-MG with shRacs or Racs OE Xenograft |
Lai et al., 2017
|
GBM |
CLX |
Glioblastoma cell line U87 and its derived cancer stem cells Xenograft |
Yang et al., 2013a
|
GBM |
CLX |
Glioblastoma cell lines U87 and U373 Xenotransplantation alone or with Mesenchymal stem cells |
Breznik et al., 2017
|
GBM |
PDX |
Primary GBM-derived cells xenografts |
Rampazzo et al., 2013
|
GBM |
PDX |
glioblastoma GBM9 cells xenografts into prkdc–/–, il2rga–/–
|
Yan et al., 2019
|
|
Medulloblastoma models
|
|
MB subgroup
|
Type of model
|
Features
|
References
|
|
WNT |
GEMM |
Ctnnb1+/−; TP53–/–
|
Gibson et al., 2010
|
WNT |
PDOX |
Xenograft of patient-derived tumor cells |
Brabetz et al., 2018; Smith et al., 2020
|
SHH |
GEMM |
Ptch1
+/−
|
Goodrich et al., 1997
|
SHH |
GEMM |
Ptch1 + /−, Trp53–/–
|
Wetmore et al., 2001
|
SHH |
GEMM |
Ptch1+/−, Cdkn2c–/–
|
Uziel et al., 2005
|
SHH |
GEMM |
SmoA2 OE |
Dey et al., 2012
|
SHH |
GEMM |
Sufu+/−, Trp53–/–
|
Lee et al., 2007
|
SHH |
GEMM |
Trp53–/– with gPtch1.1/Cas9 |
Zuckermann et al., 2015
|
Adult SHH |
GEMM |
SmoM2 OE, truncated BRPF1 OE |
Aiello et al., 2019
|
SHH |
Orthotopic xenograft |
MYCN OE in NES |
Huang et al., 2019
|
SHH |
Orthotopic xenograft |
Orthotropic xenograft of iPSC-derived NES from a Gorlin patient with a germline PTCH1 mutation |
Susanto et al., 2020
|
SHH |
PDOX |
Xenograft of patient-derived tumor cells |
Brabetz et al., 2018; Smith et al., 2020
|
Group 3 |
GEMM |
Mycn OE, Trp53–/–
|
Swartling et al., 2010
|
Group 3 |
GEMM |
GTML Trp53KI/KI
p53ERTAM
|
Hill et al., 2015
|
Group 3 |
GEMM |
Mll4
–/–
|
Dhar et al., 2018
|
Group 3 |
GEMM |
Gfi1 OE + c-MYC OE/Otx2 OE + c-MYC OE |
Ballabio et al., 2020
|
Group 3 |
Orthotopic xenograft |
Myc OE, Trp53–/–
|
Kawauchi et al., 2012; Pei et al., 2012
|
Group 3 |
Orthotopic xenograft |
MycT58A OE, Trp53 DN |
Pei et al., 2012
|
|
Glioma models
|
|
Brain tumor
|
Type of model
|
Features
|
References
|
|
Group 3 |
Orthotopic xenograft |
Myc OE, GFI1b OE |
Northcott et al., 2014
|
Group 3 |
PDOX |
Xenograft of patient-derived tumor cells |
Brabetz et al., 2018; Smith et al., 2020
|
Group 3 |
Organoid model |
Gfi1 OE + c-MYC OE/Otx2 OE + c-MYC OE |
Ballabio et al., 2020, 2021
|
Group 4 |
GEMM |
Activated SRC OE, Tp53 DN |
Forget et al., 2018
|
Group 4 |
PDOX |
Xenograft of patient-derived tumor cells |
Brabetz et al., 2018; Smith et al., 2020
|
|
Ependymoma models
|
|
Brain tumor
|
Type of model
|
Features
|
References
|
|
Ependymoma |
GEMM |
RELAFUS1
|
Ozawa et al., 2018
|
Ependymoma |
GEMM |
YAP1-MAMLD1 |
Pajtler et al., 2019
|
Ependymoma |
GEMM |
nlsYAP5SA or Lats1–/– and Lats2–/–
|
Eder et al., 2020
|
Ependymoma |
PDOX |
Xenograft of patient-derived tumor cells |
Brabetz et al., 2018; Smith et al., 2020
|
|
Meningioma models
|
|
Brain tumor
|
Type of model
|
Features
|
References
|
|
Meningioma |
CLX |
BenMen1, Me3TSC cell line xenograft |
Püttmann et al., 2005; Cargioli et al., 2007
|
Meningioma |
CLX |
CH-157-MN cell line xenograft |
Ragel et al., 2008
|
Meningioma |
CLX |
IOMM-Lee cell line xenograft |
McCutcheon et al., 2000
|
Meningioma |
PDOX |
Xenograft of patient-derived tumor cells |
McCutcheon et al., 2000
|
Meningioma |
GEMM |
Nf2
–/–
|
Kalamarides et al., 2002
|
Meningioma |
GEMM |
PDGFB OE + Nf2–/– + Cdkn2ab–/–
|
Peyre et al., 2015
|
Meningioma |
GEMM |
SmoM2 OE |
Boetto et al., 2018
|
Meningioma |
GEMM |
Nf2–/– + Ink4a–/–
|
Kalamarides et al., 2011
|
Meningioma |
PDO |
Patient-derived organoids |
Chan et al., 2021; Yamazaki et al., 2021
|